Differential effects of nebivolol vs. Metoprolol on microvascular function in hypertensive humans

Alejandro Velasco, Elizabeth Solow, Angela Price, Zhongyun Wang, Debbie Arbique, Gary Arbique, Beverley Adams-Huet, Edzard Schwedhelm, Jonathan R. Lindner, Wanpen Vongpatanasin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Use of β-adrenergic receptor (AR) blocker is associated with increased risk of fatigue and exercise intolerance. Nebivolol is a newer generation β-blocker, which is thought to avoid this side effect via its vasodilating property. However, the effects of nebivolol on skeletal muscle perfusion during exercise have not been determined in hypertensive patients. Accordingly, we performed contrast-enhanced ultrasound perfusion imaging of the forearm muscles in 25 untreated stage I hypertensive patients at rest and during handgrip exercise at baseline or after 12 wk of treatment with nebivolol (5–20 mg/day) or metoprolol succinate (100–300 mg/day), with a subsequent double crossover for 12 wk. Metoprolol and nebivolol each induced a reduction in the resting blood pressure and heart rate (130.9 ± 2.6/81.7 ± 1.8 vs. 131.6 ± 2.7/80.8 ± 1.5 mmHg and 63 ± 2 vs. 64 ± 2 beats/min) compared with baseline (142.1 ± 2.0/88.7 ± 1.4 mmHg and 75 ± 2 beats/min, respectively, both P < 0.01). Metoprolol significantly attenuated the increase in microvascular blood volume (MBV) during handgrip at 12 and 20 repetitions/min by 50% compared with baseline (mixed-model P < 0.05), which was not observed with nebivolol. Neither metoprolol nor nebivolol affected microvascular flow velocity (MFV). Similarly, metoprolol and nebivolol had no effect on the increase in the conduit brachial artery flow as determined by duplex Doppler ultrasound. Thus our study demonstrated a first direct evidence for metoprolol-induced impairment in the recruitment of microvascular units during exercise in hypertensive humans, which was avoided by nebivolol. This selective reduction in MBV without alteration in MFV by metoprolol suggested impaired vasodilation at the precapillary arteriolar level.

Original languageEnglish (US)
Pages (from-to)H118-H124
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume311
Issue number1
DOIs
StatePublished - Jul 1 2016

Fingerprint

Nebivolol
Metoprolol
Exercise
Blood Volume
Doppler Ultrasonography
Adrenergic Antagonists
Perfusion Imaging
Brachial Artery
Forearm
Vasodilation
Adrenergic Receptors

Keywords

  • Exercise
  • Hypertension
  • Muscle blood flow
  • Sympathetic nervous system

ASJC Scopus subject areas

  • Physiology
  • Medicine(all)
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Differential effects of nebivolol vs. Metoprolol on microvascular function in hypertensive humans. / Velasco, Alejandro; Solow, Elizabeth; Price, Angela; Wang, Zhongyun; Arbique, Debbie; Arbique, Gary; Adams-Huet, Beverley; Schwedhelm, Edzard; Lindner, Jonathan R.; Vongpatanasin, Wanpen.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 311, No. 1, 01.07.2016, p. H118-H124.

Research output: Contribution to journalArticle

Velasco, Alejandro ; Solow, Elizabeth ; Price, Angela ; Wang, Zhongyun ; Arbique, Debbie ; Arbique, Gary ; Adams-Huet, Beverley ; Schwedhelm, Edzard ; Lindner, Jonathan R. ; Vongpatanasin, Wanpen. / Differential effects of nebivolol vs. Metoprolol on microvascular function in hypertensive humans. In: American Journal of Physiology - Heart and Circulatory Physiology. 2016 ; Vol. 311, No. 1. pp. H118-H124.
@article{65afed9314f64016ad43eb9d37258724,
title = "Differential effects of nebivolol vs. Metoprolol on microvascular function in hypertensive humans",
abstract = "Use of β-adrenergic receptor (AR) blocker is associated with increased risk of fatigue and exercise intolerance. Nebivolol is a newer generation β-blocker, which is thought to avoid this side effect via its vasodilating property. However, the effects of nebivolol on skeletal muscle perfusion during exercise have not been determined in hypertensive patients. Accordingly, we performed contrast-enhanced ultrasound perfusion imaging of the forearm muscles in 25 untreated stage I hypertensive patients at rest and during handgrip exercise at baseline or after 12 wk of treatment with nebivolol (5–20 mg/day) or metoprolol succinate (100–300 mg/day), with a subsequent double crossover for 12 wk. Metoprolol and nebivolol each induced a reduction in the resting blood pressure and heart rate (130.9 ± 2.6/81.7 ± 1.8 vs. 131.6 ± 2.7/80.8 ± 1.5 mmHg and 63 ± 2 vs. 64 ± 2 beats/min) compared with baseline (142.1 ± 2.0/88.7 ± 1.4 mmHg and 75 ± 2 beats/min, respectively, both P < 0.01). Metoprolol significantly attenuated the increase in microvascular blood volume (MBV) during handgrip at 12 and 20 repetitions/min by 50{\%} compared with baseline (mixed-model P < 0.05), which was not observed with nebivolol. Neither metoprolol nor nebivolol affected microvascular flow velocity (MFV). Similarly, metoprolol and nebivolol had no effect on the increase in the conduit brachial artery flow as determined by duplex Doppler ultrasound. Thus our study demonstrated a first direct evidence for metoprolol-induced impairment in the recruitment of microvascular units during exercise in hypertensive humans, which was avoided by nebivolol. This selective reduction in MBV without alteration in MFV by metoprolol suggested impaired vasodilation at the precapillary arteriolar level.",
keywords = "Exercise, Hypertension, Muscle blood flow, Sympathetic nervous system",
author = "Alejandro Velasco and Elizabeth Solow and Angela Price and Zhongyun Wang and Debbie Arbique and Gary Arbique and Beverley Adams-Huet and Edzard Schwedhelm and Lindner, {Jonathan R.} and Wanpen Vongpatanasin",
year = "2016",
month = "7",
day = "1",
doi = "10.1152/ajpheart.00237.2016",
language = "English (US)",
volume = "311",
pages = "H118--H124",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "1",

}

TY - JOUR

T1 - Differential effects of nebivolol vs. Metoprolol on microvascular function in hypertensive humans

AU - Velasco, Alejandro

AU - Solow, Elizabeth

AU - Price, Angela

AU - Wang, Zhongyun

AU - Arbique, Debbie

AU - Arbique, Gary

AU - Adams-Huet, Beverley

AU - Schwedhelm, Edzard

AU - Lindner, Jonathan R.

AU - Vongpatanasin, Wanpen

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Use of β-adrenergic receptor (AR) blocker is associated with increased risk of fatigue and exercise intolerance. Nebivolol is a newer generation β-blocker, which is thought to avoid this side effect via its vasodilating property. However, the effects of nebivolol on skeletal muscle perfusion during exercise have not been determined in hypertensive patients. Accordingly, we performed contrast-enhanced ultrasound perfusion imaging of the forearm muscles in 25 untreated stage I hypertensive patients at rest and during handgrip exercise at baseline or after 12 wk of treatment with nebivolol (5–20 mg/day) or metoprolol succinate (100–300 mg/day), with a subsequent double crossover for 12 wk. Metoprolol and nebivolol each induced a reduction in the resting blood pressure and heart rate (130.9 ± 2.6/81.7 ± 1.8 vs. 131.6 ± 2.7/80.8 ± 1.5 mmHg and 63 ± 2 vs. 64 ± 2 beats/min) compared with baseline (142.1 ± 2.0/88.7 ± 1.4 mmHg and 75 ± 2 beats/min, respectively, both P < 0.01). Metoprolol significantly attenuated the increase in microvascular blood volume (MBV) during handgrip at 12 and 20 repetitions/min by 50% compared with baseline (mixed-model P < 0.05), which was not observed with nebivolol. Neither metoprolol nor nebivolol affected microvascular flow velocity (MFV). Similarly, metoprolol and nebivolol had no effect on the increase in the conduit brachial artery flow as determined by duplex Doppler ultrasound. Thus our study demonstrated a first direct evidence for metoprolol-induced impairment in the recruitment of microvascular units during exercise in hypertensive humans, which was avoided by nebivolol. This selective reduction in MBV without alteration in MFV by metoprolol suggested impaired vasodilation at the precapillary arteriolar level.

AB - Use of β-adrenergic receptor (AR) blocker is associated with increased risk of fatigue and exercise intolerance. Nebivolol is a newer generation β-blocker, which is thought to avoid this side effect via its vasodilating property. However, the effects of nebivolol on skeletal muscle perfusion during exercise have not been determined in hypertensive patients. Accordingly, we performed contrast-enhanced ultrasound perfusion imaging of the forearm muscles in 25 untreated stage I hypertensive patients at rest and during handgrip exercise at baseline or after 12 wk of treatment with nebivolol (5–20 mg/day) or metoprolol succinate (100–300 mg/day), with a subsequent double crossover for 12 wk. Metoprolol and nebivolol each induced a reduction in the resting blood pressure and heart rate (130.9 ± 2.6/81.7 ± 1.8 vs. 131.6 ± 2.7/80.8 ± 1.5 mmHg and 63 ± 2 vs. 64 ± 2 beats/min) compared with baseline (142.1 ± 2.0/88.7 ± 1.4 mmHg and 75 ± 2 beats/min, respectively, both P < 0.01). Metoprolol significantly attenuated the increase in microvascular blood volume (MBV) during handgrip at 12 and 20 repetitions/min by 50% compared with baseline (mixed-model P < 0.05), which was not observed with nebivolol. Neither metoprolol nor nebivolol affected microvascular flow velocity (MFV). Similarly, metoprolol and nebivolol had no effect on the increase in the conduit brachial artery flow as determined by duplex Doppler ultrasound. Thus our study demonstrated a first direct evidence for metoprolol-induced impairment in the recruitment of microvascular units during exercise in hypertensive humans, which was avoided by nebivolol. This selective reduction in MBV without alteration in MFV by metoprolol suggested impaired vasodilation at the precapillary arteriolar level.

KW - Exercise

KW - Hypertension

KW - Muscle blood flow

KW - Sympathetic nervous system

UR - http://www.scopus.com/inward/record.url?scp=84983772278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983772278&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00237.2016

DO - 10.1152/ajpheart.00237.2016

M3 - Article

VL - 311

SP - H118-H124

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 1

ER -